Drugs / CD62L depleted DLI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07867769 | Oct 2026 → Oct 2029 expected | disease related to hematopoietic stem cell transplant | Hong Kong Children's Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD62L depleted DLI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07867769 ↗ |
| Modality | Cell therapy | “CD62L depleted donor lymphocyte infusion (DLI)” NCT07867769 ↗ |